The WebMicroscope from Fimmic.

The WebMicroscope AI Cloud from Fimmic.

Fimmic, Helsinki, Finland, has closed a €5 million investment round to accelerate scaling of its WebMicroscope AI Cloud for tissue diagnostics. Led by new investor Ascend Capital Partners, the round brings the company’s total raised funds in 2017 to €6.6 million. Existing investors, including ACME Investments and STO-Rahoitus, also participated in the round.

Launched in early 2017, Fimmic’s WebMicroscope is a commercial platform that supports tissue diagnostics through deep learning artificial intelligence (AI)-based image analysis.

WebMicroscope aims to improve the speed and accuracy of diagnosis in order to provide more precise and personalized patient care. The instrument was recently named winner of the innovation award for artificial intelligence-based digital pathology solutions by Frost & Sullivan.

Kaisa Helminen, Fimmic.

Kaisa Helminen, Fimmic.

“Our AI algorithms have been successfully used in various applications ranging from cancer research to drug development projects on Parkinson’s disease and liver diseases,” says Kaisa Helminen, CEO of Fimmic. “The results are extremely promising, and our technology has received great interest from various industries and application areas. With this investment, we are now able to grow the team, expand our marketing actions, and launch our local activities in the US market.”

Monita Mo, Ascend Capital Partners.

Monita Mo, Ascend Capital Partners.

“AI holds great potential in several fields of medicine, including tissue diagnostics,” says Monita Mo, CEO of Ascend Capital Partners. “We were impressed about the expertise in the Fimmic team and their proven track record in executing development plans for a commercial product. We are excited to offer our experience and contact network to support Fimmic in their global expansion.”

For more information, visit Fimmic.